Making the Cardiorenal Connection with SGLT2 inhibitors

Published: 25 February 2021

  • Views:

    Views Icon 12834
  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 12834
  • Likes:

    Heart Icon 7
Part 4

of 4

All Faculty

Carol Pollock, Mark Petrie, David Cherney

Overview

This educational symposium was part of the eSPACE CRM meeting held on 22-24 January 2021.

 

The session focuses on latest data and practical implication of SGLT2 Inhibitors in Heart Failure patients.

 

eSpace CRM

This symposium was funded by an unrestricted educational grant from AstraZeneca

Learning objectives

This educational symposium will allow the audience to:

  • Understand the pathophysiological connections between cardiovascular disease and kidney disease
  • Understand how SGLT2 inhibition modifies cardiovascular and kidney function to affect patient outcomes
  • Identify individuals at risk of incident and progressive cardiorenal disease and utilise SGLT2 inhibitors appropriately for prevention and treatment of the associated conditions
  • Explain how recent guideline updates position SGLT2 inhibitors within the treatment regimen for patients with, or at risk of, cardiorenal disease

Symposium Agenda

Time - Session title and objective - Speaker(s)

  • 10 mins - Welcome and Introductions - Carol Pollock
  • 20 mins - The Cardiac Connection - Mark Petrie
  • 20 mins - The Renal Connection - David Cherney
  • 10 mins - Joined-up thinking: Evolving guidelines for cardiorenal disease management - All faculty

More from this programme

Faculty biographies